Association of the recurrence of vocal leukoplakia with MDM2-309 variants over a 2-year period: a prospective study

Abstract

Conclusion: MDM2-309 polymorphism variant genotypes decrease the risk of recurrence in vocal leukoplakia. Objective: The results of a previous study 2 years ago showed the effect of mouse double minute 2 homolog (MDM2) SNP309 polymorphisms in people with laryngeal carcinoma and vocal leukoplakia (a pre-cancerous laryngeal carcinoma lesion). This prospective, clinical trial was performed to assess the relationship between MDM2-309 polymorphism variants and recurrence/cancerization rates in people with vocal leukoplakia over a 2-year period. Participants and method: A total of 61 post-operative patients with vocal leukoplakia participated in this prospective, observational, 2-year, follow-up study, and were genotyped for the MDM2-309 gene using pyrosequencing. Recurrence and cancerization rates were used to assess the relationship between the clinical outcome and the genotype variants. Results: The recurrence rate in the GT genotypes group was lower than that in the normal TT genotype group (17.2% vs 50%, p = 0.05) and there was a significantly lower recurrence rate in the GG genotype group than in the normal TT genotype group (10% vs 50%, p = 0.03). However, there was no statistically significant difference in the cancerization rate between the MDM2-309 variant (GT + GG) genotypes group and the normal TT genotype group (12.2% vs 8.3%, p > 0.05) over the 2-year follow-up period.

Keywords:

• Cancerization
• genotype variants
• laryngeal carcinoma
• MDM2
• recurrence
• vocal leukoplakia

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grant no. 30801283), the Technology Project of Shanghai (grant nos 09QA1401000, 10QA1405900, and 14411961900), and Shanghai’s Health System of Talents Training Plan (grant nos XYQ2011055 and XYQ2011015). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Declaration of interest:

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.